About this trial
The trial will use neoadjuvant hypofractionated radiotherapy followed by surgical resection in the treatment for soft tissue sarcoma. It will allow patients to be treated over a shorter course (5 or 15 days of radiation) compared to the traditional 5 week regimen. It is proposed that this will be possible without increasing the risk of wound complication or local recurrence compared with a traditional 5 week course of pre-operative radiation.
Eligibility criteria
Qualifiers
Histologic diagnosis of a soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location)
ECOG performance status 0-2
Patient must be deemed able to comply with radiation treatment and surgery
Disqualifiers
History of prior radiation to the same area to be irradiated
Pregnancy
Active collagen vascular disease or patients genetically predisposed to increased radiation related side effects
Trial design
Treatments tested in this trial
- Ultra-Hypo-fractionation Radiotherapy
- Resection
- Questionnaire Administration
- Moderately-Hypo-fractionation Radiotherapy